Subject to shareholder approval, both Buddy CEO David McLauchlan...

First 22 Last

Share
Profile

Follow
retiredyoung

3,423 Posts.

151

28/02/19

13:19

Post #: 37603073
Share

Originally posted by benspurgin: ↑

Hi Folks

I am a very disappointed LT BUD holder. DM is like a fiction-writer, but the one thing we now know about him is that self-interest is King. Sells large tranches at high SP, performance shares aplenty, despite the delivery woes of OHM.   Having said that, why are people piling out of a stock that MUST get back to at least 8 cents, given the CR price of 8 cents and the additional commitment by all BUD BODs to take an initial position at that level? I note the position size has not been mentioned by DM. The cynical BUD (victim) holder in me can foresee them taking a thousand shares each at 8 cents, when the SP sits well below that figure!   Suckered again!

But the big boy backers for the LIFX deal will not pay 8 cents in March, 2019, if the SP is significantly below that figure.  So watch for the miraculous SP pump in the pre-signing negotiations with LIFX.

If I am correct, this daily capitulation selling into ever-new lows we are seeing in recent days will soon reverse and climb well past the CR level by mid-to late March, 2019.  Self-interest by management and the institutions can work for us here....

Loyalty is a one - way street with BUD at present.   We are financing an enigma deal wrapped in a mystery based on fluid information that is revised or forgotten at will. That is not how the ASX Disclosure Principles are supposed to work in my view.

Not happy Jan.....!

Expand

Subject to shareholder approval, both Buddy CEO David McLauchlan and Buddy Chairman Rick Borenstein will each subscribe for A$150,000 worth of Shares under the Placement.

BUD Price at posting: 6.5¢ Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

OCN

Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke

Chaos reigns markets – so let's take stock of where we're at ahead of December

PME

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

MTM

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Watchdog takes Webjet to court over alleged 'false' flight prices with hidden fees

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

SHN

Chimeric clocks $4.17M R&D tax rebate from Canberra

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

There are more pages in this discussion • 64 more messages in this thread...

First 22 Last

Add BUD (ASX) to my watchlist

Subject to shareholder approval, both Buddy CEO David McLauchlan...

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke

Chaos reigns markets – so let's take stock of where we're at ahead of December

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

Australian Rare Earths bullish on early-stage uranium potential at Overland, SA

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Watchdog takes Webjet to court over alleged 'false' flight prices with hidden fees

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Chimeric clocks $4.17M R&D tax rebate from Canberra

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game